TII
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Center (DERC) has launched a state-of-the-art facility in Tawazun Industrial Park (TIP), a regional hub for strategic businesses in the safety and security sector offering world-class business infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005302/en/
The facility comprises seven distinct workshops and five specialized laboratories. Each caters to a specific research domain from mechanical and electronics workshops, prototype test area, coil winding, armature filling, dielectric testing, and acoustic prototyping lab. The laboratories are Pulse Power Lab, Semi-Anechoic Chamber, Tempest Chamber, Acoustic Lab, and Laser Development Lab.
The facility hosts three mobile research laboratories that can be used in conjunction with the primary laboratories or be deployed in the field for outdoor testing, including two Electromagnetic Mobile Labs and a Mobile Laser Lab. Applications DERC focuses on include High-Power ElectroMagnetics (HPEM) and Electromagnetic Compatibility (EMC) testing. DERC also undertakes innovative research in the HPEM and Pulsed Power domain, along with prequalification tests for multiple industries in the region.
A first for the GCC, DERC’s facility conducts industry-leading Radio Frequency testing to manufacture and characterize high power, solid-state devices. The facility also carries out highly sensitive Acoustic experiments that require a high degree of isolation from environmental sound and vibrations, supporting development and characterization of unusual acoustic transmitters and sensors.
The controlled environment in the labs identifies involuntary sound sources in complex electronic systems that might lead to side-channel leakage. DERC’s custom-developed optical vibration analysis tools can examine mechanical system behavior across a wide range of frequencies.
Additionally, the Center has also introduced groundbreaking Signal Electronics & Acoustics (SEA) prototyping to facilitate the local development of advanced solutions like small/high-density RF and acoustic devices. The facility can undertake soldering, complex mechanical assembly, testing while advancing prototyping in 3D printing.
DERC’s Mobile Laser lab is the first of its kind in the region to conduct laser experiments outdoors to explore propagation of a high-power laser and study the effect on targets at a distance in the arid Gulf environment. Emitting a multi-kW continuous laser, the lab is equipped with a telescope mounted on a pan-tilt, focusing a beam over a distance ranging from 200 m to 2,000 m. Connected to an electrical generator, the mobile lab is designed to be used autonomously outdoors under extreme temperatures of up to 50°C.
Speaking on the new facility, Dr. Ray O. Johnson, CEO of Technology Innovation Institute (TII) and Acting CEO, ASPIRE, said: “At TII, we are committed to attracting global talent to our research centers. Given this priority, we are proud to witness DERC’s phenomenal achievement with this facility. Such innovative hubs draw a growing number of researchers as well as customers keen to benefit from testing capabilities across varied sectors.”
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center (DERC), said: “We are excited to finally witness the launch and cutting-edge capabilities of this new facility that will offer us a distinct advantage while giving the UAE much-needed autonomy when it comes to ensuring comprehensive testing and establishing a reliable supply chain.”
The Center’s achievement of bringing together multiple core capabilities under one roof provides opportunities to take HPEM testing to greater heights while enabling the testing of high-power lasers in compact environments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005302/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom